Biomarkers for the Detection and Surveillance of Renal Cancer

José Ignacio Nolazco; Simon John Christoph Soerensen; Benjamin I Chung

doi:10.1016/j.ucl.2023.01.009

Biomarkers for the Detection and Surveillance of Renal Cancer

Urol Clin North Am. 2023 May;50(2):191-204. doi: 10.1016/j.ucl.2023.01.009. Epub 2023 Feb 20.

Authors

José Ignacio Nolazco¹, Simon John Christoph Soerensen², Benjamin I Chung³

Affiliations

¹ Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, 45 Francis Street, Boston, MA 02115, USA; Servicio de Urología, Hospital Universitario Austral, Universidad Austral, Av Juan Domingo Perón 1500, B1629AHJ Pilar, Argentina. Electronic address: JNolazco@bwh.harvard.edu.
² Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, USA.
³ Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.

PMID: 36948666
DOI: 10.1016/j.ucl.2023.01.009

Abstract

Renal cell carcinoma (RCC) is a heterogeneous disease characterized by a broad spectrum of disorders in terms of genetics, molecular and clinical characteristics. There is an urgent need for noninvasive tools to stratify and select patients for treatment accurately. In this review, we analyze serum, urinary, and imaging biomarkers that have the potential to detect malignant tumors in patients with RCC. We discuss the characteristics of these numerous biomarkers and their ability to be used routinely in clinical practice. The development of biomarkers continues to evolve with promising prospects.

Keywords: Biomarkers; Diagnosis; Renal cell carcinoma; Screening.

Publication types

Review

MeSH terms

Biomarkers, Tumor
Carcinoma, Renal Cell* / diagnosis
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / diagnosis
Kidney Neoplasms* / pathology

Substances

Biomarkers, Tumor